Drugs in R & D

, Volume 1, Issue 2, pp 187–188 | Cite as


UK 109496
Section 2: Antifungal Agent Adis R&D Profile


Fluconazole Triazole Itraconazole Candidiasis Voriconazole 


  1. 1.
    Mellsop H. New antifungal agents needed for immuno-compromised patients. Inpharma 1995 Dec 2; 1015: 9–10CrossRefGoogle Scholar
  2. 2.
    Jack D. Voriconazole: a natural successor to fluconazole? Inpharma 1998 Jul 18; 1146: 7–8CrossRefGoogle Scholar
  3. 3.
    New antifungals highlighted at ICAAC. Marketletter 1997 Nov 17; 24: 26–7Google Scholar
  4. 4.
    Martin MV, Yeats J, Hitchcock CA. Voriconazole (UK-109,496): a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental Aspergillus endocarditis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 114Google Scholar
  5. 5.
    Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998 Aug; 17: 573–5PubMedGoogle Scholar
  6. 6.
    Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998 Oct; 42: 531–3PubMedCrossRefGoogle Scholar
  7. 7.
    Wildfeuer A, Seidl HP, Paule I, et al. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin. Arzneimittel Forschung 1997 Nov; 47: 1257–63PubMedGoogle Scholar
  8. 8.
    Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998 May; 31: 297–300PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations